All News

RheumNow Podcast square

Happy Diwali (11.1.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

d Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article
hip.THR_.jpg

Should They Put Off Hip Replacement Surgery?

d Jack Cush, MD

The NEJM reports what should be obvious to rheumatologists: that older adults with severe hip osteoarthritis should opt for total hip replacement (THR) over conservative exercise measures as THR yields a clinically important improvement in pain and function.

Read Article
Knee,pain,OA,DJD

GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain

d MedPage Today

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.

Read Article
Students, Studying

Medscape 2024 Medical Student Experience Survey

d Jack Cush, MD

Medscape has published a survey overview of US Medical Student impressions and experiences, satisfaction, what they think of their education and how prepared are they for the USMLE (boards) and residency.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 Inhibitor Protective Effects in Lupus

d Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
RA.Ow02.jpg

Filgotinib Efficacy and Safety - 3 Years Later

d MedPage Today

Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.

Read Article
switch.jpg

Swapping is Better than Cycling in Psoriatic Arthritis

d Jack Cush, MD

A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.

Read Article
Medscape 2024 Medical Student Experience Survey Medscape has published a survey overview of US Medical Student impressions and experiences, satisfaction, what they think of their education and how prepared are they for the USMLE (boards) and residency. https://t.co/WARsNeV3kJ https://t.co/Jaxw0CDsHD

Links:

Dr. John Cush RheumNow ( View Tweet)
EUSTAR study, 257 PSS pts. w/ 12+ mos F/U, skin Dz was 70% stable, 22% regressive, 7% progressive. Regressive skin change pts had significantly lower probability of FVC decline ≥10% & all-cause mortality (p=0.035) vs progressive patients https://t.co/3L9iVTPwKv https://t.co/NMuD8VW7Pu

Links:

Dr. John Cush RheumNow ( View Tweet)
Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI

Links:

Dr. John Cush RheumNow ( View Tweet)
How would you treat an anti-synthetase overlap pt w/ myositis, polysynovitis & rapid ILD (pt on steroids)?

Dr. John Cush RheumNow ( View Tweet)

Filgotinib Efficacy and Safety - 3 Years Later Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in… https://t.co/eABIG1Kal6 https://t.co/7ZphZALniE
Dr. John Cush RheumNow ( View Tweet)
Treatment Options for Dupuytren’s Contracture The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture. https://t.co/HTW9za8a10 https://t.co/gStCic7x2D

Links:

Dr. John Cush RheumNow ( View Tweet)
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis https://t.co/luhFvy3yjR https://t.co/52oiTYG3a4

Links:

Dr. John Cush RheumNow ( View Tweet)
STAR study shows 102 RA pts in LDA > 3 mos & pred 5 mg/d did equally well with either prednisone taper or changing to hydrocortisone 20 mg/d and taperin HC. At 12 mos both wer able to D/C GC (55% HC vs 47% pred tapering; p=0.4). https://t.co/C6YTGiF0pN

Links:

Dr. John Cush RheumNow ( View Tweet)

Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN) - 60% PGN w ≤1 g/d proteinuria (more renal recovery) - 79% w/ 1-3g/d - 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush RheumNow ( View Tweet)
Blue Collar Arthritis (10.25.2024) Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow. https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv

Links:

Dr. John Cush RheumNow ( View Tweet)
Real-world study of 76 #PsA pts (Dz Duration Psoriasis 216 mos, PsA 120 mos. No correlatons seen between skin/PASI scores and PsA clinical variables, except the signif correlation betw PASI & enthesitis (ρ = 0.285; p = 0.013). https://t.co/K6FXjE5A4N https://t.co/NVlPiPVT0s

Links:

Dr. John Cush RheumNow ( View Tweet)
Airway Dz in RA (w/o ILD dx) studied in 188 pts. Airways obst. in 21% by PFTs (assoc w/ older, male, smoking). CXR abnl in 61%, (55% bronchial thickening, 12% bronchiectasis), esp in RF+. Quant CT scan measures correlated w/ respiratory symptoms https://t.co/In1sxLZQRm https://t.co/anmUNGuby8

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×